The Formulary Management Expert Committee (FMEC) recommends that tofacitinib be reimbursed for the treatment of patients with juvenile idiopathic arthritis (JIA) provided certain conditions are met.
The Formulary Management Expert Committee (FMEC) recommends that tofacitinib be reimbursed for the treatment of patients with juvenile idiopathic arthritis (JIA) provided certain conditions are met.